Cian Healthcare Limited's Resolution Plan Implementation Committee has made significant corporate restructuring decisions following the National Company Law Tribunal's approval of its resolution plan. The committee meeting held on January 09, 2026, addressed key aspects of the company's capital restructuring and board reconstitution under the Insolvency and Bankruptcy Code framework.

Record Date Declaration

The Implementation Committee has declared January 16, 2026 as the record date for the reduction, cancellation, and extinguishment of existing paid-up equity share capital held by erstwhile promoters and existing public shareholders. This step forms a crucial part of the resolution plan implementation process approved by the NCLT on December 18, 2025.

Board Reconstitution

The committee approved the appointment of four new directors to form the interim board of directors:

The interim board's powers will remain suspended during the Resolution Plan Implementation Period, with all board powers being exercised by the Implementation Committee until the Resolution Plan Closure Date.

Fresh Equity Issuance

The committee approved the issuance of 2,37,50,000 fresh equity shares on a preferential basis to new promoters. Each share carries a face value of ₹10.00, bringing the total issuance value to ₹23,75,00,000.

Shareholding Distribution

The fresh equity shares will rank pari-passu with existing equity shares in all respects. Following this preferential allotment, the company's total issued, subscribed, and paid-up equity share capital will comprise 2,50,00,000 equity shares with a face value of ₹10.00 each, aggregating to ₹25,00,00,000.

Regulatory Compliance

All decisions were made in compliance with Regulation 30 of the SEBI Listing Regulations, relevant SEBI circulars, provisions of the Insolvency and Bankruptcy Code, and the NCLT order dated December 18, 2025. The company has committed to keeping stakeholders and regulatory authorities informed of further material developments in the resolution plan implementation process.

The Implementation Committee meeting commenced at 3:00 PM IST and concluded at 3:46 PM IST on January 09, 2026, conducted through video-conferencing under the chairmanship of Roshen Chordiya, the erstwhile Resolution Professional.

Cian Healthcare Limited has announced significant leadership changes following the approval of its resolution plan by the National Company Law Tribunal (NCLT). The pharmaceutical company informed BSE Limited about the deemed resignation of key directors and managerial personnel on December 24, 2025, as a direct consequence of the NCLT order dated December 18, 2025.

NCLT Approval and Committee Formation

The Resolution Plan Implementation Committee was constituted with effect from December 18, 2025, when the Honourable National Company Law Tribunal Bench-VI, Mumbai approved the company's resolution plan. The committee will remain operational until the Resolution Plan Closure Date as defined under the provisions of the approved resolution plan.

Committee Composition and Leadership

The Implementation Committee comprises three key members representing different stakeholder groups:

Mr. Roshen Chordiya, who previously served as the Resolution Professional of Cian Healthcare Limited, chairs the committee. He holds IBBI Registration No. IBBI/IPA-001/IP-P02840/2023-2024/14347.

Deemed Resignation of Key Personnel

The Implementation Committee, in its meeting held on December 24, 2025, noted the vacancy at the office due to deemed resignation of the following erstwhile directors and key managerial personnel:

All resignations are deemed effective from December 18, 2025, pursuant to the NCLT order approving the resolution plan. The company clarified that the requirement for resignation letters is not applicable as these vacations of office result directly from the NCLT order.

Independent Director Confirmation

In a subsequent disclosure dated December 27, 2025, the company provided additional confirmation regarding the resignation of Mr. Sunil Kumar, the erstwhile Independent Non-Executive Director. Through a letter dated December 24, 2025, Mr. Sunil Kumar confirmed that there are no other material reasons for his vacation of office (deemed resignation) except pursuant to the NCLT Order and the resolution plan approved therein.

Official Disclosure and Documentation

The formal disclosure was submitted to BSE Limited with reference number CIAN/BSE/2025-26/02, providing comprehensive details about each personnel's deemed resignation. The Implementation Committee meeting (CIAN/RPIC/2025-26/01) commenced at 05:30 P.M. (IST) and concluded at 06:07 P.M. (IST) on December 24, 2025. A follow-up disclosure with reference number CIAN/BSE/2025-26/03 was submitted on December 27, 2025, containing the confirmation from Mr. Sunil Kumar.

Regulatory Compliance and References

The disclosure was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company referenced multiple regulatory circulars including SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.

Corporate Details and Operations

Cian Healthcare Limited operates as an ISO 9001:2015 and WHO GMP certified pharmaceutical company. The company's registered office is located at Office No. 301, 3rd Floor, Konark Icon, Mundhwa-Kharadi Road, Kirtane Baugh, Magarpatta, Hadapsar, Pune-411028. Its manufacturing facility is situated at Kh. No: 248, Village Sisor, Bhagwanpur, Roorkee, Haridwar, Pin-247661, Uttarakhand.

The company continues under the Corporate Insolvency Resolution Process with the newly constituted Implementation Committee overseeing the transition and ensuring compliance with the approved resolution plan terms.